



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



**NOTICE IS HEREBY GIVEN** that a meeting of the Regulation Revision Committee has been ordered and called for 8:30 a.m. on Thursday, June 13, 2019 at the Board office, for the purpose to wit:

## AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

**Revised 06-10-2019**

1. Call to Order
2. Quorum Call
3. Call for Additional Agenda Items & Adoption of Agenda
4. Opportunity for Public Comment
5. Consideration of Minutes from Previous Meeting – April 24, 2019
6. Old Business
  - a. Compounding in nuclear pharmacies [04-01-2015]
  - b. Review of centralized prescription dispensing (LAC 46:LIII.1141) [08-23-2017]
  - c. Review of NABP Model Rules for Automated Medication Systems and Telepharmacy [03-23-2018]
  - d. Review of PMP Law and request for FraudRx<sup>®</sup> Alert access to PMP Database [08-15-2018]
  - e. Review of Proposed Memorandum of Understanding between FDA and the States re Distribution of Compounded Drug Products [10-19-2018]
  - f. Rule for automated medication systems to allow correctional centers [11-14-2018]
  - Consideration of Regulatory Proposal 2019-C ~ Automated Medication Systems (Drafts #2 & #3)***
  - g. Patient identification cards in medical marijuana program [11-14-2018]
  - h. Regulation of prescription video games [02-19-2019]
  - i. Pharmacy staffing and patient safety [03-08-2019]
  - j. Prescription adaptation [03-08-2019]

---

**NOTE:** Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purpose of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

**NOTE:** While it is possible members of the Board who are not members of this committee may attend this committee meeting in sufficient number to constitute a quorum of the Board, no action taken at this committee meeting may be construed as an action of the entire Board.

6. Old Business (cont.)
  - k. USP-800 Stakeholder Subcommittee [03-19-2019]
7. New Business
  - a. HB-138 / Act 2019-\_\_\_ *Effective 08-01-2019* [06-10-2019]
  - b. HB-284 / Act 2019-\_\_\_ *Effective 08-01-2019* [06-10-2019]
  - c. HB-358 / Act 2019-\_\_\_ *Effective 08-01-2019* [06-10-2019]
  - Consideration of Regulatory Proposal 2019-E ~ Cannabis MDI (Draft #1)*
  - d. HB-375 / Act 2019-\_\_\_ *Effective 08-01-2019* [06-10-2019]
  - e. HB-433 / Act 2019-161 *Effective 06-06-2019* [06-10-2019]
  - f. SB-041 / Act 2019-124 *Effective 08-01-2019 and 07-01-2020* [06-10-2019]
  - Consideration of Regulatory Proposal 2019-G ~ Pharmacy Benefit Managers (Draft #1)*
  - g. SB-053 / Act 2019-080 *Effective 08-01-2019* [06-10-2019]
  - Consideration of Regulatory Proposal 2019-F ~ PMP Access in Federal Jurisdictions (Draft #1)*
  - h. SB-099 / Act 2019-052 *Effective 08-01-2019* [06-10-2019]
8. Adjourn

---

**NOTE:** Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purpose of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

**NOTE:** While it is possible members of the Board who are not members of this committee may attend this committee meeting in sufficient number to constitute a quorum of the Board, no action taken at this committee meeting may be construed as an action of the entire Board.